HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
50 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
MPO
myeloperoxidase
Chromosome 17 Β· 17q22
NCBI Gene: 4353Ensembl: ENSG00000005381.9HGNC: HGNC:7218UniProt: P05164
696PubMed Papers
21Diseases
1Drugs
15Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
RESEARCH IMPACT
Highly Studied
CLINICAL
Clinical TrialsOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
hydrogen peroxide catabolic processnucleosome bindingprotein-containing complex destabilizing activitynucleosome disassemblymyeloperoxidase deficiencyAlzheimer disease type 1multiple system atrophyamyotrophic lateral sclerosis
✦AI Summary

Myeloperoxidase (MPO) is a heme peroxidase predominantly expressed in neutrophils and monocytes that serves dual roles in immunity and pathological inflammation. Functionally, MPO catalyzes the production of hypochlorous acid and other hypohalous acids from hydrogen peroxide, generating antimicrobial reactive oxygen species that enhance neutrophil killing of bacteria and fungi 1. Beyond microbicidal activity, MPO mediates proteolytic cleavage of alpha-1-microglobulin to form t-alpha-1-microglobulin, which inhibits low-density lipoprotein oxidation and limits vascular damage 2. MPO operates through oligomeric-dependent mechanisms: dimeric MPO disassembles nucleosomes to facilitate neutrophil extracellular trap (NET) formation, while monomeric MPO stably binds NETs to produce hypohalous acids extracellularly 3. Clinically, MPO is implicated in multiple diseases through oxidative mechanisms. In anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, anti-MPO antibodies drive necrotizing glomerulonephritis via complement pathway activation, with therapeutic benefit demonstrated through C5aR/CD88 blockade 4. MPO-generated oxidants contribute to atherosclerosis pathogenesis by oxidizing lipoproteins in arterial lesions 5 and mediates stroke pathogenesis through vascular injury, NET formation, oxidative stress, and blood-brain barrier disruption 6. In kidney disease, the MPO-hydrogen peroxide-chloride system generates chlorinated protein adducts causing cellular dysfunction 7. MPO expression is regulated by LXR and PPARalpha ligands, linking its expression to cholesterol homeostasis 8.

Sources cited
1
MPO catalyzes production of hypochlorous acid and other toxic intermediates that enhance PMN microbicidal activity
PMID: 9922160
2
MPO mediates proteolytic cleavage of alpha-1-microglobulin to form t-alpha-1-microglobulin, which inhibits LDL oxidation and limits vascular damage
PMID: 25698971
3
Dimeric MPO disassembles nucleosomes to facilitate NET formation; monomeric MPO binds stably to NETs to produce hypohalous acids extracellularly
PMID: 40963017
4
Anti-MPO antibodies drive necrotizing crescentic glomerulonephritis via complement activation; C5aR/CD88 blockade ameliorates disease
PMID: 24179165
5
MPO-catalyzed oxidation of proteins and lipoproteins in atherosclerotic lesions implicates MPO in atherosclerosis pathogenesis
PMID: 10946213
6
MPO contributes to stroke pathogenesis through vascular injury, NET formation, oxidative stress, and blood-brain barrier disruption
PMID: 40379076
7
MPO-hydrogen peroxide-chloride system generates chlorinated protein and lipid adducts causing dysfunction in glomerular and tubulointerstitial kidney disease
PMID: 14633118
8
Human MPO expression is regulated by LXR and PPARalpha ligands through an Alu receptor response element in the promoter
PMID: 16956579
Disease Associationsβ“˜21
myeloperoxidase deficiencyOpen Targets
0.77Strong
Alzheimer disease type 1Open Targets
0.49Moderate
multiple system atrophyOpen Targets
0.29Weak
amyotrophic lateral sclerosisOpen Targets
0.24Weak
Alzheimer diseaseOpen Targets
0.14Weak
Parkinson diseaseOpen Targets
0.13Weak
Abnormality of the skeletal systemOpen Targets
0.13Weak
neoplasmOpen Targets
0.12Weak
coronary artery diseaseOpen Targets
0.12Weak
microscopic polyangiitisOpen Targets
0.11Weak
ganglioneuromaOpen Targets
0.11Weak
interstitial lung diseaseOpen Targets
0.11Weak
atrial fibrillationOpen Targets
0.11Weak
idiopathic pulmonary fibrosisOpen Targets
0.11Weak
chronic obstructive pulmonary diseaseOpen Targets
0.11Weak
acute myocardial infarctionOpen Targets
0.11Weak
COVID-19–associated multisystem inflammatory syndrome in adultsOpen Targets
0.11Weak
Granulomatosis with PolyangiitisOpen Targets
0.11Weak
strokeOpen Targets
0.10Weak
Churg-Strauss syndromeOpen Targets
0.10Weak
Myeloperoxidase deficiencyUniProt
Pathogenic Variants15
NM_000250.2(MPO):c.249-2A>GLikely pathogenic
Myeloperoxidase deficiency;Alzheimer disease type 1|Myeloperoxidase deficiency|Acute myeloid leukemia
β˜…β˜…β˜†β˜†2025
NM_000250.2(MPO):c.1705C>T (p.Arg569Trp)Pathogenic
Myeloperoxidase deficiency|not provided|Alzheimer disease type 1;Myeloperoxidase deficiency|MPO-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 569
NM_000250.2(MPO):c.1555_1568del (p.Met519fs)Pathogenic
Myeloperoxidase deficiency|not provided|MPO-related disorder
β˜…β˜…β˜†β˜†2024β†’ Residue 519
NM_000250.2(MPO):c.721C>T (p.Gln241Ter)Pathogenic
Myeloperoxidase deficiency|MPO-related disorder
β˜…β˜…β˜†β˜†2023β†’ Residue 241
NM_000250.2(MPO):c.1281del (p.Thr428fs)Likely pathogenic
not provided|Myeloperoxidase deficiency
β˜…β˜…β˜†β˜†2023β†’ Residue 428
NM_000250.2(MPO):c.760_764del (p.Gln254fs)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2024β†’ Residue 254
NM_000250.2(MPO):c.402G>A (p.Trp134Ter)Likely pathogenic
Myeloperoxidase deficiency
β˜…β˜†β˜†β˜†2024β†’ Residue 134
NM_000250.2(MPO):c.1711C>T (p.Arg571Ter)Likely pathogenic
Myeloperoxidase deficiency
β˜…β˜†β˜†β˜†2023β†’ Residue 571
NM_000250.2(MPO):c.817dup (p.Ala273fs)Likely pathogenic
Myeloperoxidase deficiency
β˜…β˜†β˜†β˜†2022β†’ Residue 273
NM_000250.2(MPO):c.403C>T (p.Arg135Ter)Pathogenic
Myeloperoxidase deficiency
β˜…β˜†β˜†β˜†2019β†’ Residue 135
NM_000250.2(MPO):c.1621+2T>CLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2017
NM_000250.2(MPO):c.604dup (p.Glu202fs)Likely pathogenic
MPO-related disorder
β˜†β˜†β˜†β˜†2024β†’ Residue 202
NM_000250.2(MPO):c.1495C>T (p.Arg499Cys)Pathogenic
Myeloperoxidase deficiency|MPO-related disorder
β˜†β˜†β˜†β˜†2024β†’ Residue 499
NM_000250.2(MPO):c.1501G>A (p.Gly501Ser)Pathogenic
Myeloperoxidase deficiency
β˜†β˜†β˜†β˜†2007β†’ Residue 501
NM_000250.2(MPO):c.1715T>G (p.Leu572Trp)Pathogenic
Myeloperoxidase deficiency
β˜†β˜†β˜†β˜†2004β†’ Residue 572
View on ClinVar β†—
Drug Targets1
VERDIPERSTATPhase III
Myeloperoxidase inhibitor
multiple system atrophy
Related Genes
AZU1Protein interaction100%BPIProtein interaction100%CAMPProtein interaction100%MS4A3Protein interaction100%CEACAM8Protein interaction100%CTSGProtein interaction100%
Tissue Expression6 tissues
Bone Marrow
100%
Lung
0%
Brain
0%
Liver
0%
Heart
0%
Ovary
0%
Gene Interaction Network
Click a node to explore
MPOAZU1BPICAMPMS4A3CEACAM8CTSG
PROTEIN STRUCTURE
Preparing viewer…
PDB5MFA Β· 1.20 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.99LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.80 [0.64–0.99]
RankingsWhere MPO stands among ~20K protein-coding genes
  • #309of 20,598
    Most Researched696 Β· top 5%
  • #2,427of 5,498
    Most Pathogenic Variants15
  • #9,532of 17,882
    Most Constrained (LOEUF)0.99
Genes detectedMPO
Sources retrieved50 papers
Response timeβ€”
πŸ“„ Sources
50β–Ό
1
C5a receptor (CD88) blockade protects against MPO-ANCA GN.
PMID: 24179165
J Am Soc Nephrol Β· 2014
1.00
2
Developmental and differential regulation of human MPO gene in leukemic cells.
PMID: 2165203
Leukemia Β· 1990
0.92
3
Myeloperoxidase transforms chromatin into neutrophil extracellular traps.
PMID: 40963017
Nature Β· 2025
0.90
4
Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy.
PMID: 37656254
Basic Res Cardiol Β· 2023
0.82
5
Biosynthesis of human myeloperoxidase.
PMID: 29408362
Arch Biochem Biophys Β· 2018
0.80